hepat
c
viru
hcv
major
caus
agent
liver
diseas
worldwid
major
infect
peopl
develop
lifelong
chronic
infect
current
therapeut
protocol
base
combin
administr
ribavirin
unabl
erad
viru
signific
number
patient
thu
crucial
improv
current
protocol
investig
new
therapeut
approach
viral
infect
specif
natur
immun
cooper
provid
host
defens
viral
hepat
interact
immun
respons
virusinfect
hepatocyt
repres
key
event
initi
control
viral
replic
protect
develop
diseas
sever
data
indic
control
clearanc
hepat
b
viru
hbv
hcv
infect
may
provid
direct
noncytolyt
antivir
activ
solubl
factor
among
differ
kind
cell
involv
earli
immun
lymphocyt
known
exert
broad
antivir
activ
differ
virus
retroviru
flaviviru
paramyxoviru
orthomyxoviru
picornaviru
coronaviru
arenaviru
herpesviru
hepadnaviru
orthopox
viru
intrahepat
lymphocyt
chronic
hepat
c
patient
higher
degre
necroinflammatori
liver
diseas
belong
cell
subset
cell
polyclon
activ
recruit
liver
suggest
involv
hcv
liver
patholog
differ
decreas
cell
subset
observ
peripher
blood
patient
chronic
hepat
c
compar
either
control
respond
therapi
suggest
cellspecif
involv
antivir
immun
respons
interestingli
cell
activ
sever
nonpeptid
antigen
pyrophosphomonoest
alkylamin
ncontain
bisphosphon
moreov
ncontain
bisphosphon
drug
known
zoledron
zol
bromohydrin
pyrophosph
brhpp
drug
call
phosphostim
current
use
oncolog
therapi
preclin
trial
work
analyz
abil
activ
lymphocyt
exert
noncytolyt
antivir
activ
hcv
use
model
subgenom
hcv
replic
hepatoma
cell
observ
activ
peripher
lymphocyt
nonpeptid
antigen
induc
noncytolyt
inhibit
subgenom
hcv
replic
neutral
experi
shown
effect
mediat
indic
modul
lymphocytemedi
noncytolyt
antivir
activ
nonpeptid
drug
may
provid
novel
approach
immunotherapi
hcv
infect
human
hepatoma
cell
line
harbor
hcv
replicon
previous
describ
hcv
replicon
present
cell
carri
previous
describ
adapt
mutat
determin
sequenc
cell
parent
cell
line
ie
contain
hcv
replicon
maintain
dmem
life
technolog
milan
itali
supplement
fetal
bovin
serum
fb
mm
lglutamin
u
penicillin
streptomycin
recombin
human
peprotech
london
uk
scheringplough
kenilworth
nj
usa
use
induc
hcv
replicon
clearanc
previous
describ
blood
sampl
obtain
either
healthi
donor
hcv
patient
pbmc
isol
ficollhypaqu
gradient
pharmacia
biotech
piscataway
nj
usa
cell
purifi
pbmc
immunomagnet
separ
use
magnet
microbead
miltenyi
biotec
bergisch
gladbach
germani
puriti
cell
fraction
experi
measur
flow
cytometr
analysi
data
shown
cocultur
cell
maintain
rpmi
supplement
fb
mm
lglutamin
u
penicillin
streptomycin
cell
line
obtain
stimul
pbmc
healthi
donor
isopentenyl
pyrophosph
ipp
u
day
cell
cell
per
well
cocultur
flatbottom
plate
presenc
either
pbmc
cell
per
well
purifi
cell
cell
per
well
rpmidmem
medium
ratio
supplement
describ
avoid
heterolog
contact
pbmc
isol
cell
cultur
pore
size
semiperm
polycarbon
membran
transwel
chamber
bd
labwar
franklin
lake
nj
usa
cocultur
left
untreat
stimul
ipp
sigma
st
loui
mo
usa
zoledron
acid
zol
novarti
basel
switzerland
brhpp
ng
kindli
provid
innatepharma
marseil
franc
analysi
cytokin
product
supernat
collect
h
cocultur
experi
cell
parent
cell
line
pretreat
differ
dose
zol
h
wash
twice
cocultur
cell
line
rpmidmem
medium
ratio
h
product
evalu
intracellular
stain
flow
cytometri
pbmc
cell
wash
pb
contain
bsa
sodium
azid
incub
min
follow
mab
mab
clone
coupl
fitc
clone
clone
antihladr
clone
coupl
pe
bd
bioscienc
mountain
view
ca
usa
sampl
wash
twice
pb
bsa
fix
pfa
acquir
facscalibur
flow
cytomet
bd
bioscienc
total
event
acquir
sampl
analyz
cellquest
softwar
becton
dickinson
immunocytometri
system
san
jose
ca
usa
analysi
cytokin
product
perform
use
cytometr
bead
assay
cba
use
human
cba
kit
bd
bioscienc
cocultur
supernat
collect
h
analyz
product
tumor
necrosi
accord
manufactur
instruct
data
analyz
cba
softwar
becton
dickinson
frequenc
cell
examin
singlecel
analysi
flow
cytometri
previous
describ
pbmc
stimul
overnight
ipp
zol
brhpp
ng
brefeldin
serva
heidelberg
germani
ad
h
stimul
block
intracellular
transport
cocultur
experi
hepatoma
cell
cell
line
brefeldin
ad
h
begin
cocultur
cell
pbmc
cell
line
wash
twice
pb
bsa
sodium
azid
stain
mab
clone
min
sampl
fix
pfa
min
incub
anticytokinespecif
mab
clone
clone
dilut
pb
bsa
saponin
cell
final
wash
twice
pb
bsa
saponin
acquir
facscalibur
becton
dickinson
total
rna
extract
trizol
reagent
gibco
brl
life
technolog
ny
usa
accord
manufactur
instruct
revers
transcript
rt
amplif
hcv
perform
previous
describ
number
hcv
replicon
copi
measur
realtim
quantit
pcr
target
region
hcv
use
abi
prism
sequenc
detect
system
appli
biosystem
applera
italia
itali
one
microgram
total
rna
use
rt
reaction
use
multiscrib
revers
transcriptas
random
hexam
method
appli
biosytem
primer
probe
follow
forward
primer
revers
primer
taqman
probe
fam
appli
biosystem
amplif
perform
reaction
mixtur
contain
templat
taqman
univers
pcr
master
mix
appli
biosystem
nm
primer
nm
probe
follow
activ
uracilnglycosylas
ung
min
activ
amplitaq
gold
min
cycl
amplif
min
perform
standard
curv
obtain
use
known
concentr
hcv
repliconencod
plasmid
cytokin
neutral
assay
achiev
use
rabbit
polyclon
antiserum
either
origin
titer
neutral
unit
nu
origin
titer
nu
obtain
laboratori
total
nu
neutral
antibodi
incub
either
supernat
pbmc
stimul
ipp
h
differ
dose
recombin
min
neutral
supernat
ad
cell
cultur
presenc
hcv
rna
analyz
day
previous
describ
explor
solubl
factor
releas
activ
cell
exert
antivir
activ
hcv
replicon
pbmc
isol
two
healthi
donor
cocultur
cell
carri
subgenom
hcv
replicon
cellcontactfre
cultur
system
use
transwel
insert
order
specif
activ
cell
use
ipp
nonpeptid
compound
known
select
trigger
popul
day
cocultur
total
rna
extract
level
hcv
rna
determin
analysi
notabl
shown
fig
ipp
stimul
cocultur
induc
dramat
reduct
hcv
rna
level
cell
lane
lane
donor
respect
independ
contact
ipp
affect
per
se
hcv
replic
lane
hand
effect
hcv
rna
level
observ
unstimul
pbmc
lane
lane
donor
respect
indic
ipp
activ
necessari
induc
inhibit
hcv
replic
suggest
therefor
direct
involv
cell
known
inhibit
subgenom
hcv
replic
use
control
lane
similar
result
obtain
use
pbmc
isol
healthi
donor
data
shown
notabl
flow
cytometr
analysi
pbmc
confirm
ipp
stimul
induc
express
differ
activ
marker
hladr
exclus
lymphocyt
surfac
donor
analyz
data
shown
sinc
convent
semiquantit
techniqu
quantifi
extent
hcv
replicon
inhibit
induc
ippstimul
pbmc
realtim
pcr
shown
fig
b
ipp
stimul
pbmc
induc
reduct
hcv
rna
level
similar
reduct
thu
confirm
result
obtain
semiquantit
test
whether
antivir
activ
directli
mediat
cell
due
bystand
activ
cell
cell
purifi
magnet
bead
use
cocultur
total
pbmc
pure
cell
donor
cocultur
cell
either
presenc
absenc
ipp
shown
fig
c
purifi
cell
abl
inhibit
subgenom
hcv
replic
similar
extent
total
pbmc
popul
stimul
ipp
lane
respect
altogeth
data
demonstr
cell
subset
stimul
nonpeptid
antigen
ipp
exert
direct
antivir
activ
mediat
solubl
factor
order
understand
solubl
factor
respons
hcv
replic
inhibit
analyz
presenc
subset
cytokin
releas
ippactiv
cell
supernat
pbmc
cocultur
stimul
ipp
collect
h
differ
cytokin
simultan
analyz
cba
figur
show
result
obtain
differ
experi
unstimul
pbmc
produc
none
cytokin
detect
cba
system
antigen
stimul
induc
drastic
increas
product
pg
pg
pg
cytokin
mainli
releas
cell
fact
intracellular
stain
assay
pbmc
cultur
h
presenc
ipp
show
stimul
induc
high
frequenc
cell
fig
c
total
cell
respect
contrast
bystand
product
cytokin
cell
signific
respect
confirm
ipp
select
activ
cell
determin
specif
role
ippinduc
product
inhibit
hcv
replic
perform
antibodyblock
assay
experi
use
cellfre
supernat
supernat
obtain
cell
stimul
ipp
differ
period
time
abl
inhibit
hcv
replic
cell
similar
extent
cocultur
fig
lane
data
shown
thu
confirm
ippstimul
cell
produc
cytokin
exert
antivir
activ
hypothesi
support
observ
block
activ
specif
neutral
antibodi
significantli
reduc
hcv
replic
inhibit
fig
lane
contrari
impair
hcvinhibitori
activ
observ
use
neutral
antibodi
either
data
shown
fig
lane
control
neutral
activ
mab
use
experi
cell
treat
two
known
inhibitor
hcv
replic
either
presenc
absenc
specif
neutral
mab
fig
lane
lane
respect
expect
mab
abl
block
hcv
replicon
clearanc
even
high
dose
cytokin
fig
lane
lane
respect
worthi
note
high
concentr
recombin
abl
influenc
hcv
rna
level
data
shown
data
demonstr
antivir
activ
ippactiv
cell
mainli
mediat
product
known
ncontain
bisphosphon
zol
pyrophosphomonoest
phosphostim
brhpp
two
drug
use
clinic
therapi
trial
respect
activ
cell
ask
therefor
whether
drug
abl
induc
cellmedi
hcv
clearanc
shown
fig
cocultur
treat
zol
brhpp
inhibit
subgenom
hcv
replic
lane
respect
similar
extent
ipp
stimul
lane
antivir
activ
mediat
pbmc
activ
sinc
effect
viral
replic
per
se
observ
data
shown
notabl
peripher
cell
releas
respons
either
zol
brhpp
fig
indic
drug
well
ipp
stimul
may
induc
hcv
replicon
clearanc
product
sinc
known
zol
induc
recognit
target
cell
lymphocyt
ask
whether
presenc
hcv
replicon
could
affect
mechan
contact
system
hcv
repliconcarri
cell
parent
cell
line
ie
contain
hcv
replicon
either
left
untreat
pretreat
increas
dose
zol
h
extens
wash
cocultur
cell
line
puriti
h
product
cell
analyz
intracellular
stain
assay
notabl
shown
fig
c
absenc
zol
stimul
cell
well
parent
cell
line
induc
signific
product
cell
thu
indic
hcv
replicon
per
se
abl
trigger
lymphocyt
activ
hand
zol
pretreat
cell
induc
similar
product
cell
thu
suggest
zol
induc
cell
activ
hcvindepend
indirect
mechan
probabl
accumul
mevalon
metabolit
cell
test
cell
hcv
patient
could
activ
nonpeptid
antigen
analyz
drugstimul
hcv
pbmc
product
hcv
replicon
clearanc
induct
show
fig
ipp
brhpp
zol
abl
induc
releas
cell
hcv
patient
similar
extent
observ
healthi
donor
verifi
releas
hcv
cell
suffici
biolog
activ
induc
hcv
replicon
clearanc
cocultiv
hcv
pbmc
presenc
ipp
brhpp
zol
day
cocultur
presenc
hcv
rna
analyz
repres
experi
shown
fig
b
demonstr
pbmc
hcv
patient
stimul
ipp
brhpp
zol
abl
induc
clearanc
hcv
replicon
lane
respect
altogeth
data
demonstr
cell
present
peripher
blood
hcv
patient
could
stimul
nonpeptid
antigen
exert
antivir
activ
hcv
patient
specif
innat
immun
frequent
unabl
erad
infect
moreov
current
regimen
base
ribavirin
effect
consider
number
hcv
patient
therefor
develop
addit
therapeut
approach
need
studi
take
advantag
subgenom
hcv
replicon
system
hepatoma
cell
analyz
antihcv
activ
cell
major
contribut
work
find
lymphocyt
exert
antivir
activ
hcv
activ
nonpeptid
antigen
found
ipp
stimul
either
pbmc
highli
purifi
lymphocyt
induc
drastic
inhibit
hcv
replic
antivir
activ
mediat
releas
noncytolyt
antivir
factor
sinc
independ
contact
obtain
use
supernat
ippstimul
cultur
use
neutral
antibodi
demonstr
cellcultur
system
inhibit
hcv
replic
exert
releas
result
line
abil
recombin
inhibit
hcv
replicon
replic
identifi
popul
effector
cell
ippmedi
antivir
activ
although
complet
rule
possibl
effect
contamin
effector
cell
intracellular
stain
experi
demonstr
main
cell
lymphocyt
moreov
abil
highli
purifi
lymphocyt
inhibit
hcv
replic
strongli
suggest
cell
popul
like
main
mediat
antivir
activ
shown
hcvspecif
cell
abl
inhibit
hcv
replic
direct
cytolyt
effect
cytokinemedi
activ
find
extend
cell
innat
immun
capabl
induc
activ
hcv
evid
cell
mediat
antivir
activ
releas
noncytolyt
solubl
factor
alreadi
report
human
immunodefici
viru
infect
sever
data
indic
cell
exert
cytolyt
noncytolyt
antivir
activ
releas
macrophag
inflammatori
protein
regul
activ
normal
express
secret
rant
consid
anoth
flaviviru
west
nile
viru
adopt
transfer
cell
mice
reduc
suscept
mice
viru
vitro
cocultur
system
protect
effect
vivo
primarili
due
product
key
molecul
immun
respons
viral
infect
modul
innat
adapt
immun
respons
stimul
sever
intracellular
pathway
directli
suppress
viral
replic
without
kill
host
cell
hcv
infect
abil
cell
produc
acut
phase
associ
viral
clearanc
human
chronic
hcvinfect
patient
impair
peripheralspecif
cell
produc
hepat
expans
hcvspecif
cell
regulatori
phenotyp
report
moreov
chimpanze
expans
multispecif
sustain
cell
respons
associ
resolut
hcv
infect
data
indic
establish
chronic
infect
may
associ
statu
low
inflamm
level
could
lead
inhibit
immun
respons
expans
cell
thu
suggest
product
could
one
key
event
resolut
hcv
infect
util
contact
cultur
condit
show
hcv
repliconcarri
cell
abl
stimul
product
cell
howev
sinc
util
subgenom
hcv
replicon
lack
structur
protein
complet
rule
cell
involv
recognit
hcvinfect
hepatocyt
data
suggest
cell
spite
appar
lack
specif
viru
recognit
could
play
import
role
immun
respons
virus
releas
like
noncytolyt
solubl
factor
interest
featur
cell
biolog
possibl
induc
activ
nonpeptid
antigen
cell
shown
releas
cytokin
mediat
cytoreduct
effect
myeloma
cell
activ
ncontain
bisphosphon
moreov
phosphostimactiv
cell
kill
autolog
metastat
renal
carcinoma
show
nonpeptid
antigen
zol
brhpp
abl
induc
hcv
replicon
clearanc
mediat
pbmc
deriv
healthi
donor
importantli
hcv
patient
cell
releas
directli
stimul
nonpeptid
antigen
indic
least
peripher
blood
cell
hcv
patient
could
specif
activ
drug
interestingli
nonpeptid
antigen
alreadi
clinic
use
thu
suggest
feasibl
approach
human
altogeth
data
suggest
cell
hcv
patient
could
stimul
releas
solubl
factor
use
noncytolyt
antivir
activ
immunoregulatori
function
import
adapt
respons
therefor
celltarget
immunotherapi
aim
boost
cell
may
complement
tradit
therapeut
regimen
current
use
treat
chronic
hcv
infect
